1.
Nat Biotechnol
; 25(2): 179-84, 2007 Feb.
Article
in English
| MEDLINE
| ID: mdl-17287749
ABSTRACT
Five years after the US anthrax attacks, and more than two years after BioShield legislation was ratified, a survey reveals that biodefense funding has thus far produced only a handful of products for clinical development.
Subject(s)
Biotechnology/economics , Bioterrorism/economics , Civil Defense/economics , Clinical Medicine/economics , Drug Industry/economics , Technology Transfer , Vaccines/economics , Bioterrorism/prevention & control , United States
2.
Nat Biotechnol
; 23(6): 672-6, 2005 Jun.
Article
in English
| MEDLINE
| ID: mdl-15940233
Subject(s)
Biotechnology/economics , Industry/economics , Capital Financing , Europe , International Cooperation , Investments , United States
3.
Nat Biotechnol
; 21(11): 1287-91, 2003 Nov.
Article
in English
| MEDLINE
| ID: mdl-14595356
Subject(s)
Biotechnology/economics , Biotechnology/trends , Capital Financing/economics , Capital Financing/trends , Entrepreneurship/economics , Entrepreneurship/trends , Investments/economics , Investments/trends , Biotechnology/statistics & numerical data , Capital Financing/methods , Capital Financing/statistics & numerical data , Entrepreneurship/statistics & numerical data , Europe , Investments/statistics & numerical data , Ownership/economics , Ownership/statistics & numerical data , Ownership/trends
4.
Nat Biotechnol
; 21(6): 613-7, 2003 Jun.
Article
in English
| MEDLINE
| ID: mdl-12776144
